Health
Europe’s Super‑bug Surge Threatens Hospital Patients as Antibiotic Options Shrink
WHO warns that resistant Klebsiella, E. coli and Acinetobacter infections have risen sharply across Europe, while more than 16 countries lack coordinated AMR plans and diagnostic testing remains limited.
Escalating Hospital Super‑bugs
Between 2019 and 2025 infections caused by the hospital bacterium Klebsiella pneumoniae grew by an estimated 72 percent, far above the five‑percent reduction target set by WHO. In the same period, infections with Escherichia coli that are resistant to cephalosporin antibiotics increased by more than 16 percent, missing a 10 percent decline goal. WHO’s analysis shows that at least half of Klebsiella pneumoniae samples across Europe are now resistant to key antibiotics, and roughly one‑in‑two European countries report similar resistance in Acinetobacter isolates. On a positive note, bloodstream infections caused by resistant Acinetobacter have almost halved since the peak levels observed in 2021.
Patchy National Strategies
The joint WHO‑ECDC assessment found that more than 16 of the 51 countries examined still lack a standardized national approach or coordinated mechanism to combat antimicrobial resistance. This policy gap limits systematic surveillance, hampers data sharing and weakens the implementation of infection‑control measures. In many hospitals, few blood cultures are taken, forcing clinicians to choose antibiotics without knowing which will be effective. WHO stresses that expanding diagnostic testing would enable patients to receive the right drug sooner and would give governments a clearer picture of resistance trends, allowing more targeted interventions and better allocation of resources.
Clinical Consequences and System Strain
When first‑line antibiotics fail, patients are significantly more likely to die during their hospital stay, according to WHO data. Clinicians then resort to carbapenems, but rising resistance to these drugs leaves only a small group of last‑resort medicines, many of which are costly and not readily available in all European nations. Each erosion of an antimicrobial defence line pushes patients closer to having no effective treatment options at all. For health systems, the lack of reliable resistance data means planning is effectively “half‑blind,” undermining resource allocation, infection‑control programmes and the ability to protect the most vulnerable patients.